These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 27166684)

  • 1. The Impact of Conventional and Biological Disease Modifying Antirheumatic Drugs on Bone Biology. Rheumatoid Arthritis as a Case Study.
    Barreira SC; Fonseca JE
    Clin Rev Allergy Immunol; 2016 Aug; 51(1):100-9. PubMed ID: 27166684
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of TNF α antagonist therapy on bone metabolism in rheumatoid arthritis: a systematic review.
    Sakthiswary R; Das S
    Curr Drug Targets; 2013 Dec; 14(13):1552-7. PubMed ID: 23848441
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disease-modifying antirheumatic drugs and bone mass in rheumatoid arthritis.
    Di Munno O; Delle Sedie A; Rossini M; Adami S
    Clin Exp Rheumatol; 2005; 23(2):137-44. PubMed ID: 15895881
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Scientific basis for the efficacy of combined use of antirheumatic drugs against bone destruction in rheumatoid arthritis.
    Suematsu A; Tajiri Y; Nakashima T; Taka J; Ochi S; Oda H; Nakamura K; Tanaka S; Takayanagi H
    Mod Rheumatol; 2007; 17(1):17-23. PubMed ID: 17278017
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Rheumatoid arthritis and bone -periarticular and systemic bone loss-].
    Ono K; Ohashi S; Tanaka S
    Clin Calcium; 2013 Feb; 23(2):249-55. PubMed ID: 23354093
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term effects of infliximab on bone and cartilage turnover markers in patients with rheumatoid arthritis.
    Chopin F; Garnero P; le Henanff A; Debiais F; Daragon A; Roux C; Sany J; Wendling D; Zarnitsky C; Ravaud P; Thomas T
    Ann Rheum Dis; 2008 Mar; 67(3):353-7. PubMed ID: 17644538
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New biologics for rheumatoid arthritis.
    Choy E
    J R Coll Physicians Edinb; 2011 Sep; 41(3):234-7. PubMed ID: 21949922
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Secondary osteoporosis. Bisphosphonates as a possible strategy for the prevention of bone destruction in rheumatoid arthritis].
    Suzuki Y
    Clin Calcium; 2007 Dec; 17(12):1909-13. PubMed ID: 18057668
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relation among anti-rheumatic drug therapy, CD14(+)CD16(+) blood monocytes and disease activity markers (DAS28 and US7 scores) in rheumatoid arthritis: A pilot study.
    Amoruso A; Sola D; Rossi L; Obeng JA; Fresu LG; Sainaghi PP; Pirisi M; Brunelleschi S
    Pharmacol Res; 2016 May; 107():308-314. PubMed ID: 27045818
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanisms and therapeutic targets for bone damage in rheumatoid arthritis, in particular the RANK-RANKL system.
    Tanaka Y; Ohira T
    Curr Opin Pharmacol; 2018 Jun; 40():110-119. PubMed ID: 29702364
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disease-modifying antirheumatic drug use in the elderly rheumatoid arthritis patient.
    Ranganath VK; Furst DE
    Clin Geriatr Med; 2005 Aug; 21(3):649-69, viii. PubMed ID: 15911212
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lipid profile of rheumatoid arthritis patients treated with anti-tumor necrosis factor-alpha drugs changes according to disease activity and predicts clinical response.
    Cacciapaglia F; Anelli MG; Rinaldi A; Serafino L; Covelli M; Scioscia C; Iannone F; Lapadula G
    Drug Dev Res; 2014 Nov; 75 Suppl 1():S77-80. PubMed ID: 25381986
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of disease-modifying antirheumatic drugs (DMARDs) on bone homeostasis in rheumatoid arthritis (RA) patients.
    Khoshroo A; Ramezani K; Moghimi N; Bonakdar M; Ramezani N
    Inflammopharmacology; 2023 Apr; 31(2):689-697. PubMed ID: 36348208
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Are glucocorticoids harmful to bone in early rheumatoid arthritis?
    Lems WF
    Ann N Y Acad Sci; 2014 May; 1318():50-4. PubMed ID: 24739059
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IL-6 receptor inhibition positively modulates bone balance in rheumatoid arthritis patients with an inadequate response to anti-tumor necrosis factor therapy: biochemical marker analysis of bone metabolism in the tocilizumab RADIATE study (NCT00106522).
    Karsdal MA; Schett G; Emery P; Harari O; Byrjalsen I; Kenwright A; Bay-Jensen AC; Platt A
    Semin Arthritis Rheum; 2012 Oct; 42(2):131-9. PubMed ID: 22397953
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Biochemical markers of bone turnover. New aspect. Therapy of rheumatoid arthritis for bone metabolic marker].
    Okada Y; Nawata M; Tanaka Y
    Clin Calcium; 2009 Aug; 19(8):1186-90. PubMed ID: 19638703
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of long-term disease-modifying antirheumatic drugs on endothelial function in patients with early rheumatoid arthritis.
    Turiel M; Tomasoni L; Sitia S; Cicala S; Gianturco L; Ricci C; Atzeni F; De Gennaro Colonna V; Longhi M; Sarzi-Puttini P
    Cardiovasc Ther; 2010 Oct; 28(5):e53-64. PubMed ID: 20337633
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disease-modifying antirheumatic drug use in the elderly rheumatoid arthritis patient.
    Ranganath VK; Furst DE
    Rheum Dis Clin North Am; 2007 Feb; 33(1):197-217. PubMed ID: 17367700
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial.
    Cohen SB; Dore RK; Lane NE; Ory PA; Peterfy CG; Sharp JT; van der Heijde D; Zhou L; Tsuji W; Newmark R;
    Arthritis Rheum; 2008 May; 58(5):1299-309. PubMed ID: 18438830
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Update on the use of conventional disease-modifying antirheumatic drugs in the management of rheumatoid arthritis.
    Feely MG; O'Dell JR
    Curr Opin Rheumatol; 2010 May; 22(3):316-20. PubMed ID: 20190639
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.